Angiogenesis and lymphangiogenesis: Highlights of the past year

Current Opinion in Hematology

Volumn 11, Issue 4, 2004, Pages 262-271

  Luttun, Aernout ^a   Carmeliet, Peter ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

Angiogenesis; Collateral growth; Placental growth factor; Vascular endothelial growth factor; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BEVACIZUMAB; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; HOMEODOMAIN PROTEIN; MATRIX METALLOPROTEINASE; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; OXYGEN; RECOMBINANT VASCULOTROPIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSCRIPTION FACTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C;

ANGIOGENESIS; ARTERY; CELL HETEROGENEITY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG INHIBITION; DRUG POTENTIATION; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYPOXIA; KIDNEY CANCER; LYMPH VESSEL; LYMPHANGIOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; SURVIVAL TIME; VEIN;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANTIBODIES, MONOCLONAL; EXTRACELLULAR MATRIX; HUMANS; LYMPHANGIOGENESIS; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; OXYGEN; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 4344605204     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000126936.58889.95     Document Type: Review

References (157)

1. Jain RK: Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693. An excellent and complete review covering various aspects of blood and lymphatic vessel formation in the embryo and the adult.
2. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9:653-660. See [1].
3. Cleaver O, Melton DA: Endothelial signaling during development. Nat Med 2003, 9:661-668. See [1].
4. Lohela M, Saaristo A, Veikkola T, et al.: Lymphangiogenic growth factors, receptors and therapies. Thromb Haemost 2003, 90:167-184. See [1].
5. Rafii S, Lyden D: Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003, 9:702-712. See [1].
6. Jain RK, Duda DG: Role of bone marrow-derived cells in tumor angiogenesis and treatment. Cancer Cell 2003, 3:515-516.
7. Machein MR, Renninger S, de Lima-Hahn E, et al.: Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003, 13:582-597. This warrants for careful estimation of EPC contribution to neovascularization, because in some cases their contribution may be lower than anticipated.
8. De Palma M, Venneri MA, Roca C, et al.: Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 2003, 9:789-795. See [7].
9. Stoll BR, Migliorini C, Kadambi A, et al.: A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003, 102:2555-2561. Mathematical models, as provided in this study, may importantly contribute to estimate the dependency of tumors on EPCs and thus predict the chances of success when targeting EPCs.
10. Garcia-Barros M, Paris F, Cordon-Cardo C, et al.: Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
11. Lyden D, Hattori K, Dias S, et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-1201. This study highlights the important synergism between hematopoietic and endothelial precursors in their contribution to tumor vascularization.
12. Rehman J, Li J, Orschell CM, et al.: Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation 2003, 107:1164-1169.
13. Loomans CJ, De Koning EJ, Staal FJ, et al.: Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53:195-199. This study argues in favor of the use of exogenous functional EPCs to overcome endogenous EPC dysfunction in certain patients.
14. Scheubel RJ, Zorn H, Silber RE, et al.: Age-dependent depression in circulating endothelial progenitor cells in patients undergoing coronary artery by-pass grafting. J Am Coll Cardiol 2003, 42:2073-2080. See [13].
15. Schuch G, Heymach JV, Nomi M, et al.: Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003, 63:8345-8350.
16. Willett CG, Boucher Y, Di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147. This reference strengthens the observations made in [145] and [146] and provides the precise mechanisms by which VEGF antibody compromises the tumor vasculature.
17. Salven P, Mustjoki S, Alitalo R, et al.: VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 2003, 101:168-172. This study suggests the existence of lymphatic endothelial precursors, a concept that may be therapeutically exploited in lymphedema.
18. Gerety SS, Wang HU, Chen ZF, et al.: Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 1999, 4:403-414.
19. Seki T, Yun J, Oh SP: Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003, 93:682-689.
20. Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998, 93:741-753.
21. Chi JT, Chang HY, Haraldsen G, et al.: Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A 2003, 100:10623-10628. Elaborate study of the molecular differences between endothelia in different vascular beds. This and the recent discovery of tissue-specific angiogenic growth factors should enable the direction of therapeutic stimulation or regression of blood vessel growth to the diseased target tissue without causing side effects.
22. Kidd KR, Weinstein BM: Fishing for novel angiogenic therapies. Br J Pharmacol 2003, 140:585-594.
23. Lawson ND, Scheer N, Pham VN, et al.: Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 2001, 128:3675-3683.
24. Zhong TP, Childs S, Leu JP, et al.: Gridlock signalling pathway fashions the first embryonic artery. Nature 2001, 414:216-220.
25. Lawson ND, Vogel AM, Weinstein BM: Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev Cell 2002, 3:127-136. This is a study of the molecular cascade that induces arterial specification. That the cascade involves classical angiogenic factors like VEGF and angiopoietins underscores the rather unexpected concept that those factors actually differentiate between venous and arterial endothelial cells.
26. Lawson ND, Mugford JW, Diamond BA, et al.: Phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development. Genes Dev 2003, 17:1346-1351. See [25].
27. Mukouyama YS, Shin D, Britsch S, et al.: Sensory nerves determine the pattern of arterial differentiation and blood vessel branching in the skin. Cell 2002, 109:693-705. See [25].
28. Visconti RP, Richardson CD, Sato TN: Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A 2002, 99:8219-8224.
29. Liu ZJ, Shirakawa T, Li Y, et al.: Regulation of Notch1 and DII4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003, 23:14-25.
30. Hirakawa S, Hong YK, Harvey N, et al.: Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003, 162:575-586. The identification of lymphatic endothelial-specific markers has been a very important hinge point for the unraveling of lymphangiogenic mechanisms and the identification of lymphangiogenic growth factors.
31. Petrova TV, Makinen T, Makela TP, et al.: Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002, 21:4593-4599. This study highlights the molecular diversity between blood vascular and lymphatic endothelial cells - knowledge that is crucial for specifically manipulating both vessel types. Moreover, it reports the intriguing observation that fully differentiated blood vessel endothelial cells may change fate by overexpression of Prox-1.
32. Yuan L, Moyon D, Pardanaud L, et al.: Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002, 129:4797-4806.
33. Schacht V, Ramirez MI, Hong YK, et al.: T1 alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003, 22:3546-3556.
34. Gale NW, Thurston G, Hackett SF, et al.: Angiopoietin-2 is required for post-natal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423.
35. Karkkainen MJ, Haiko P, Sainio K, et al.: Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004, 5:74-80. This study establishes a direct link between VEGF-C and lymphangiogenesis before and after birth. Although Prox-1 may commit cells to a lymphatic endothelial fate, VEGF-C is necessary for sprouting of lymphatic endothelial cells.
36. Abtahian F, Guerriero A, Sebzda E, et al.: Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk. Science 2003, 299:247-251.
37. Ober EA, Olofsson B, Makinen T, et al.: Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep 2004, 5:78-84.
38. Saaristo A, Veikkola T, Tammela T, et al.: Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med 2002, 196:719-730. This study provides important proof of the principle that lymphatic endothelial cell growth can be specifically stimulated in vivo without affecting blood vascular growth by using genetically engineered VEGF-C.
39. Rissanen TT, Markkanen JE, Gruchala M, et al.: VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003, 92:1098-1106.
40. Yoon YS, Murayama T, Gravereaux E, et al.: VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003, 111:717-725.
41. Szuba A, Skobe M, Karkkainen MJ, et al.: Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEBJ 2002, 16:1985-1987.
42. Padera TP, Kadambi A, di Tomaso E, et al.: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
43. Streit M, Detmar M: Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003, 22:3172-3179.
44. Jeltsch M, Tammela T, Alitalo K, Wilting J: Genesis and pathogenesis of lymphatic vessels. Cell Tissue Res 2003, 314:69-84.
45. Nisato RE, Tille JC, Pepper MS: Lymphangiogenesis and tumor metastasis. Thromb Haemost 2003, 90:591-597.
46. Onogawa S, Kitadai Y, Tanaka S, et al.: Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci 2004, 95:32-39.
47. Yokoyama Y, Charnock-Jones DS, Licence D, et al.: Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003, 88:237-244.
48. Arap W, Kolonin MG, Trepel M, et al.: Steps toward mapping the human vasculature by phage display. Nat Med 2002, 8:121-127.
49. Luttun A, Carmeliet P: De novo vasculogenesis in the heart. Cardiovasc Res 2003, 58:378-389.
50. McIntosh DP, Tan XY, Oh P, Schnitzer JE: Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery. Proc Natl Acad Sci U S A 2002, 99:1996-2001.
51. Nanda A, St Croix B: Tumor endothelial markers: new targets for cancer therapy. Curr Opin Oncol 2004, 16:44-49.
52. LeCouter J, Lin R, Frantz G, et al.: Mouse endocrine gland-derived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 2003, 144:2606-2616. This study reports on the mouse homologue of human EG-VEGF (see [53]), an endocrine gland-specific angiogenic growth factor. The existence of these growth factors is an interesting feature for organ-specific therapeutic stimulation or regression of blood vessels.
53. LeCouter J, Lin R, Ferrara N: Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 2002, 8:913-917.
54. Kisliouk T, Levy N, Hurwitz A, et al.: Presence and regulation of endocrine gland vascular endothelial growth factor/prokineticin-1 and its receptors in ovarian cells. J Clin Endocrinol Metab 2003, 88:3700-3707.
55. Wernert N, Okuducu AF, Pepper MS: Ets 1 is expressed in capillary blood vessels but not in lymphatics. J Pathol 2003, 200:561-567.
56. Lee SW, Kim WJ, Choi YK, et al.: SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat Med 2003, 9:900-906.
57. Gerhardt H, Golding M, Fruttiger M, et al.: VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 2003, 161:1163-1177. This elegant study reveals the difference in endothelial phenotype and responsiveness to angiogenic growth factors, depending on the status of involvement in the angiogenesis process.
58. Anderson CR, Ponce AM, Price RJ: Absence of OX-43 antigen expression in invasive capillary sprouts: identification of a capillary sprout-specific endothelial phenotype. Am J Physiol Heart Circ Physiol 2004, 286:H346-H353.
59. Yamazaki D, Suetsugu S, Miki H, et al.: WAVE2 is required for directed cell migration and cardiovascular development. Nature 2003, 424:452-456.
60. Carmeliet P: Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet 2003, 4:710-720. This review, together with [77] and [78], reveals the important anatomic and physiologic links between the vascular system and the nervous system. Unveiling such links is of utmost importance in the identification of possible unexpected side effects of angiogenic or antiangiogenic therapies.
61. Afzal A, Shaw LC, Caballero S, et al.: Reduction in preretinal neovascularization by ribozymes that cleave the A2B adenosine receptor mRNA. Circ Res 2003, 93:500-506.
62. Serini G, Valdembri D, Zanivan S, et al.: Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424:391-397. This study reveals a nonneuronal function for the neurorepellant semaphorin3A, establishing an important parallel between the ways in which neurons and endothelial cells are guided to their target.
63. Gu C, Rodriguez ER, Reimert DV, et al.: Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Dev Cell 2003, 5:45-57.
64. van der Zwaag B, Hellemons AJ, Leenders WP, et al.: PLEXIN-D1, a novel plexin family member, is expressed in vascular endothelium and the central nervous system during mouse embryogenesis. Dev Dyn 2002, 225:336-343.
65. Augustin HG, Reiss Y: EphB receptors and ephrinB ligands: regulators of vascular assembly and homeostasis. Cell Tissue Res 2003, 314:25-31.
66. Wang B, Xiao Y, Ding BB, et al.: Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity. Cancer Cell 2003, 4:19-29. This study identifies an angiogenic role for certain members of a novel category of angiogenic factors stemming from the neurogenesis field, thereby paving the way for many more exciting studies of the possible involvement of other family members in blood vessel formation.
67. Lee EW, Michalkiewicz M, Kitlinska J, et al.: Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003, 111:1853-1862.
68. Lee EW, Grant DS, Movafagh S, et al.: Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 2003, 24:99-106.
69. Ekstrand AJ, Cao R, Bjorndahl M, et al.: Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A 2003, 100:6033-6038.
70. Compernolle V, Brusselmans K, Acker T, et al.: Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002, 8:702-710. This study identifies a role for VEGF-VEGFR-2 interactions on pneumocytes in lung maturation, a mechanism that might be therapeutically exploited in preterm babies with respiratory distress syndrome.
71. LeCouter J, Moritz DR, Li B, et al.: Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003, 299:890-893. This study unveils an unprecedented role for VEGFR-1 in liver protection, by instructing the liver endothelium to produce liver trophic factors, a paracrine effect that may be unique to the liver vascular bed.
72. Zhang H, Vutskits L, Pepper MS, et al.: VEGF is a chemoattractant for FGF-2-stimulated neural progenitors. J Cell Biol 2003, 163:1375-1384.
73. Fabel K, Tam B, Kaufer D, et al.: VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci 2003, 18:2803-2812.
74. Jiang S, Dong Z, Zhu D, et al.: Local tissue hypoxia and formation of nasal polyps. Chin Med J (Engl) 2003, 116:243-247.
75. Li B, Xu W, Luo C, et al.: VEGF-induced activation of the PI3-K/Akt pathway reduces mutant SOD1-mediated motor neuron cell death. Brain Res Mol Brain Res 2003, 111:155-164.
76. Qiu MH, Zhang R, Sun FY: Enhancement of ischemia-induced tyrosine phosphorylation of Kv1.2 by vascular endothelial growth factor via activation of phosphatidylinositol 3-kinase. J Neurochem 2003, 87:1509-1517.
77. Lambrechts D, Storkebaum E, Morimoto M, et al.: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 2003, 34:383-394. This elaborate study further extends the findings reported in [78] and convincingly links VEGF to amyotrophic lateral sclerosis, using a multispecies approach involving studies in mice and humans.
78. Oosthuyse B, Moons L, Storkebaum E, et al.: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001, 28:131-138. This mouse study reports a link between amyotrophic lateral sclerosis and VEGF, in part by a direct effect of VEGF on motor neuron survival, and provides a useful model for studying late-onset motor neuron degeneration, a key feature of amyotrophic lateral sclerosis.
79. Storkebaum E, Carmeliet P: VEGF: a critical player in neurodegeneration. J Clin Invest 2004, 113:14-18.
80. Yamakawa M, Liu LX, Date T, et al.: Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003, 93:664-673.
81. Kleiman NS, Patel NC, Allen KB, et al.: Evolving revascularization approaches for myocardial ischemia. Am J Cardiol 2003, 92:9N-17N.
82. Elson DA, Thurston G, Huarig LE, et al.: Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev 2001, 15:2520-2532.
83. Shyu KG, Wang MT, Wang BW, et al.: Intramyocardial injection of naked DNA encoding HIF-1alpha/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc Res 2002, 54:576-583.
84. Vincent KA, Shyu KG, Luo Y, et al.: Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000, 102:2255-2261.
85. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732. This extensive review illustrates the complexity of HIFs and their regulation.
86. Mabjeesh NJ, Escuin D, LaVallee TM, et al.: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003, 3:363-375.
87. Cramer T, Yamanishi Y, Clausen BE, et al.: HIF-1 alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
88. Carmeliet P, Dor Y, Herbert JM, et al.: Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
89. Cayre A, Rossignol F, Clottes E, et al.: aHIF but not HIF-1 alpha transcript is a poor prognostic marker in human breast cancer. Breast Cancer Res 2003, 5:R223-R230.
90. Blouw B, Song H, Tihan T, et al.: The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003, 4:133-146. This study introduces the important concept that the environment of the tumor determines its response to hypoxia. Such location-dependent differences should be taken into account in the design of antitumoral therapies.
91. Epstein AC, Gleadle JM, McNeill LA, et al.: C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001, 107:43-154. This study unravels a mechanism by which HIF is directly regulated by oxygen concentration and identifies the new class of prolyl hydroxylases that modify proline residues in HIF, a posttranslational modification that is necessary for association with the Von Hippel Lindau protein and subsequent degradation of HIF.
92. Pugh CW, Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684. See [85].
93. Hagen T, Taylor CT, Lam F, et al.: Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1 alpha. Science 2003, 302:1975-1978.
94. Berra E, Benizri E, Ginouves A, et al.: HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 alpha in normoxia. EMBO J 2003, 22:4082-4090.
95. Erez N, Milyavsky M, Eilam R, et al.: Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1 alpha activation and inhibits tumor growth. Cancer Res 2003, 63:8777-8783.
96. Warnecke C, Griethe W, Weidemann A, et al.: Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003, 17:1186-1188.
97. Lyden D, Young AZ, Zagzag D, et al.: Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677.
98. Volpert OV, Pili R, Sikder HA, et al.: Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2002, 2:473-483.
99. Ruzinova MB, Schoer RA, Gerald W, et al.: Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. Cancer Cell 2003, 4:277-289. This study highlights the important concept that the pathologically more relevant autochthonous tumor models may show a different susceptibility to antiangiogenic therapy than the more frequently used xenograft models.
100. Sikder H, Huso DL, Zhang H, et al.: Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4:291-299. See [99].
101. Gorski DH, Walsh K: Control of vascular cell differentiation by homeobox transcription factors. Trends Cardiovasc Med 2003, 13:213-220.
102. Wu Y, Moser M, Bautch VL, et al.: HoxB5 is an upstream transcriptional switch for differentiation of the vascular endothelium from precursor cells. Mol Cell Biol 2003, 23:5680-5691.
103. Myers C, Charboneau A, Cheung I, et al.: Sustained expression of homeobox D10 inhibits angiogenesis. Am J Pathol 2002, 161:2099-2109.
104. Hansen SL, Myers CA, Charboneau A, et al.: HoxD3 accelerates wound healing in diabetic mice. Am J Pathol 2003, 163:2421-2431.
105. Gorski DH, Leal AJ: Inhibition of endothelial cell activation by the homeobox gene Gax J Surg Res 2003, 111:91-99.
106. Maeshima Y, Sudhakar A, Lively JC, et al.: Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
107. Hamano Y, Zeisberg M, Sugimoto H, et al.: Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601. This study highlights a mechanism by which tumstatin can specifically inhibit blood vessel formation in tumors without affecting normal blood vessels. The finding of such pathology-specific mechanisms may help to increase the safety profile of antiangiogenic therapies.
108. Sudhakar A, Sugimoto H, Yang C, et al.: Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003, 100:4766-4771.
109. Brigstock DR: Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis 2002, 5:153-165.
110. Lin CG, Leu SJ, Chen N, et al.: CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J Biol Chem 2003, 278:24200-24208.
111. Babic AM, Kireeva ML, Kolesnikova TV, et al.: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1998, 95:6355-6360.
112. Mo FE, Muntean AG, Chen CC, et al.: CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002, 22:8709-8720.
113. Ivkovic S, Yoon BS, Popoff SN, et al.: Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130:2779-2791.
114. Lake AC, Bialik A, Walsh K, et al.: CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility. Am J Pathol 2003, 162:219-231.
115. Perbal B, Brigstock DR, Lau LF: Report on the second international workshop on the CCN family of genes. Mol Pathol 2003, 56:80-85.
116. Heissig B, Hattori K, Friedrich M, et al.: Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases. Curr Opin Hematol 2003, 10:136-141.
117. Seo DW, Li H, Guedez L, et al.: TIMP-2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003, 114:171-180. This work highlights an antiangiogenic role for two different members of the TIMP family, independent of their MMP-inhibitory role, thereby revealing a plausible explanation for the disappointing results of recent antiangiogenesis trials based on MMP inhibition.
118. Conway EM, Carmeliet P: Cardiovascular biology: signalling silenced. Nature 2003, 425:139-141.
119. Qi JH, Ebrahem Q, Moore N, et al.: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9:407-415. See [117].
120. Tian X-L, Kadaba R, You S-A, et al.: Positional cloning of an angiogenic factor gene: VG5Q mutations cause susceptibility to Klippel-Trenaunay syndrome. Nature 2004, (in press). This study identifies a new angiogenic factor, VG5Q, as one of the susceptibility genes predisposing to the vascular malformations of the Klippel-Trenaunay syndrome, a congenital vascular malformation disease, many of which have an unknown molecular basis in part because of the sporadic occurrence and mosaic body distribution of these lesions.
121. Chan CK, Pham LN, Chinn C, et al.: Mouse strain-dependent heterogeneity of resting limbal vasculature. Invest Ophthalmol Vis Sci 2004, 45:441-447. This study identifying loci that modulate known angiogenesis genes is of significant importance for finding new angiogenic substances.
122. Fukino K, Sata M, Seko Y, et al.: Genetic background influences therapeutic effectiveness of VEGF. Biochem Biophys Res Commun 2003, 310:143-147. See [121].
123. Rogers MS, Rohan RM, Birsner AE, et al.: Genetic loci that control vascular endothelial growth factor-induced angiogenesis. FASEB J 2003, 17:2112-2114. See [121].
124. Cross LM, Cook MA, Lin S, et al.: Rapid analysis of angiogenesis drugs in a live fluorescent zebrafish assay. Arterioscler Thromb Vasc Biol 2003, 23:911-912.
125. Habeck H, Odenthal J, Walderich B, et al.: Analysis of a zebrafish VEGF receptor mutant reveals specific disruption of angiogenesis. Curr Biol 2002, 12:1405-1412.
126. Stalmans I, Lambrechts D, De Smet F, et al.: VEGF: a modifier of the del22q11 (DiGeorge) syndrome? Nat Med 2003, 9:173-182. This study highlights the importance of genetic interactions and the involvement of VEGF in the pathogenesis of DiGeorge syndrome, using a multispecies approach involving mice, zebrafish, and humans.
127. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 2000, 103:211-225.
128. Carmeliet P, Moons L, Luttun A, et al.: Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583. This study is an important landmark study that unveils a modulatory role for PIGF and its receptor Flt-1 in angiogenesis and amply demonstrates the therapeutic implications thereof.
129. Autiero M, Waltenberger J, Communi D, et al.: Role of PIGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003, 9:936-943. See [128].
130. Luttun A, Tjwa M, Moons L, et al.: Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002, 8:831-840. See [128].
131. Pipp F, Heil M, lssbrucker K, et al.: VEGFR-1-selective VEGF homologue PIGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003, 92:378-385. Carefully conducted study that independently confirms the findings in [130] that PIGF stimulates collateral growth in part by targeting inflammatory cells.
132. Hattori K, Heissig B, Wu Y, et al.: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 2002, 8:841-849. This study complements the findings in [130] on a role of PIGF and its receptor VEGFR-1 in recruitment of hematopoietic precursors and identifies both a direct and indirect mechanism for this.
133. Gerber HP, Malik AK, Solar GP, et al.: VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417:954-958. This study unveils the role of angiogenic factors VEGF and PIGF and their receptors in hematopoietic stem cell proliferation and survival and thereby highlights the close association between angiogenesis and hematopoiesis.
134. Simons M, Ware JA: Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov 2003, 2:863-871.
135. Cao R, Brakenhielm E, Pawliuk R, et al.: Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003, 9:604-613.
136. Dixelius J, Makinen T, Wirzenius M, et al.: Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J Biol Chem 2003, 278:40973-40979. This study provides a potential mechanism for the angiogenic versus lymphangiogenic effect signaled through the VEGFR-3 receptor.
137. Spiegel S, Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003, 4:397-407.
138. Miura S, Matsuo Y, Saku K: Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 2003, 41:1118-1123.
139. Bergers G, Song S, Meyer-Morse N, et al.: Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295. This study proposes a remedy for treatment of end-stage tumors (in which VEGF-receptor targeting of the tumor endothelium alone often fails) by using combination therapy directed against both endothelial cells and smooth muscle cells or pericytes that sometimes stabilize tumor vessels.
140. Kerbel R, Folkman J: Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
141. Carmeliet P, Ferreira V, Breier G, et al.: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380:435-439.
142. Ferrara N, Carver-Moore K, Chen H, et al.: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380:439-442.
143. Ferrara N: VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2:795-803.
144. Stadler W, Wilding G: Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol 2003, 46(Suppl):S41-S47.
145. McCarthy M: Antiangiogenesis drug promising for metastatic colorectal cancer. Lancet 2003; 361:1959. This study constitutes a milestone in angiogenesis research by providing the first report of clinical success of antiangiogenesis tumor therapy.
146. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434. See [145].
147. Alavi A, Hood JD, Frausto R, et al.: Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301:94-96.
148. Bocci G, Francia G, Man S, et al.: Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A 2003, 100:12917-12922.
149. Freedman SB, Isner JM: Therapeutic angiogenesis for coronary artery disease. Ann Intern Med 2002, 136:54-71.
150. Henry TD, Annex BH, McKendall GR, et al.: The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003, 107:1359-1365,
151. Rajagopalan S, Mohler E 3rd, Lederman RJ, et al.: Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial. Am Heart J 2003, 145:1114-1118.
152. Hedman M, Hartikainen J, Syvanne M, et al.: Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003, 107:2677-2683. This study reports encouraging results in the therapeutic stimulation of blood vessel growth in patients.
153. Losordo DW, Vale PR, Hendel RC, et al.: Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002, 105:2012-2018. See [152].
154. Simons M, Annex BH, Laham RJ, et al.: Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002, 105:788-793.
155. Lederman RJ, Mendelsohn FO, Anderson RD, et al.: Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002, 359:2053-2058.
156. Grines CL, Watkins MW, Mahmarian JJ, et al.: A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol 2003, 42:1339-1347. See [152].
157. Tomita N, Morishita R, Taniyama Y, et al.: Angiogenic property of hepatocyte growth factor is dependent on upregulation of essential transcription factor for angiogenesis, ets-1. Circulation 2003, 107:1411-1417.